The advent of immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1, has revolutionized the management of advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.